Which synthetic biology startup is growing the fastest?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
Profluent is the fastest-growing private synthetic biology startup we can identify today, with Cradle close behind and Arzeda making the strongest case from actual product commercialization.
There is no single clean growth metric in synthetic biology. Profluent is accelerating through strategic partnerships, Cradle through enterprise usage, Arzeda through product penetration, Antheia through commercial manufacturing, and Solugen from a much larger industrial base.
Profluent’s lead is not really about the headline $2.25 billion Lilly figure. The stronger evidence is the sequence: rapid financing growth, a roughly 3.2x jump in implied private valuation, more serious counterparties, and broader use of its AI-designed gene-editing systems.
Cradle is the closest challenger because its growth looks more like a recurring software business. It went from 21+ customers and 31 proteins to 50+ active projects, six top-25 pharmaceutical customers, multiyear expansions, and newer deployments with Bayer and Lundbeck.
Arzeda has the cleanest proof that synthetic biology can move from AI-designed biology into a real market. ViaLeaf launched in 2024, exceeded 5% of the global Reb M market in 2025, expanded production, and then moved into an exclusive global production and commercialization arrangement with MANE.
That makes the ranking unusually sensitive to what the reader values. If “growth” means actual products taking market share, Arzeda has a better case than Profluent. If it means customer expansion, Cradle may already be the strongest.
Antheia is at a different stage again. It has already shipped commercial thebaine and is building toward repeat pharmaceutical supply across a pipeline of more than 70 biosynthetic ingredients, so the next test is whether one successful commercial product becomes several.
Solugen remains one of the most industrially mature companies in the group, but the freshest public data is operational rather than company-wide financial data. We can see large-scale deliveries and capacity expansion; we cannot cleanly calculate its recent revenue growth.
The wider pattern is that synthetic biology investors are becoming less impressed by platform ambition on its own. The companies standing out are the ones showing that biology is reaching customers, production lines, procurement budgets, or repeat scientific workflows.
Our ranking therefore separates scale from acceleration. Solugen may still be larger than several companies above it, but Profluent’s strategic position is changing faster, Cradle’s usage is deepening faster, and Arzeda’s product commercialization is easier to verify.
The biggest weakness in Profluent’s number-one position is revenue visibility. A few strong recurring-revenue disclosures from Cradle, or clearer commercial economics from Arzeda, could change the ranking quickly. For now, though, Profluent has the broadest combination of fresh growth indicators moving at once.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
Which synthetic biology startup is growing the fastest?
Why is it so hard to name the fastest-growing synthetic biology startup today?
The fastest-growing synthetic biology startup today depends heavily on what we count as growth, because Profluent, Cradle, Arzeda, Antheia and Solugen are scaling very different kinds of businesses.
A company selling industrial chemicals can show tonnes produced, orders and revenue. A protein-design software company can show customers and projects. A biotech platform may sign pharmaceutical deals worth billions on paper years before those programs produce meaningful revenue. Funding adds another layer of confusion because private valuations can rise much faster than the underlying business.
That problem has become harder to ignore lately. Synthetic biology investors are paying much more attention to what reaches customers after the industry spent years rewarding ambitious platforms long before commercial scale arrived. SynBioBeta calculated roughly $12.2 billion of sector investment in 2024, a rebound from the previous two years, but capital has become far more concentrated around companies that can show a route from biology to actual demand.
The companies rising fastest reflect that change. Profluent has accumulated major gene-editing partnerships at unusual speed. Cradle is getting its protein-engineering software deeper into pharmaceutical R&D. Arzeda has taken an AI-designed product into an existing global ingredient market. Antheia is manufacturing pharmaceutical starting materials commercially. Solugen already operates at industrial scale.
There is no honest way to collapse all five into one obvious metric.
| Company | What is growing fastest | What we still cannot see clearly |
|---|---|---|
| Profluent | Major partnerships and strategic value | Current revenue |
| Cradle | Enterprise projects and pharma adoption | Current revenue |
| Arzeda | Commercial product penetration | Company-wide sales |
| Antheia | Commercial manufacturing capability | Recurring customer volumes |
| Solugen | Industrial production | Recent company-wide growth rate |
What does “growing fastest” actually mean for a synthetic biology startup?
For a synthetic biology startup, we think growth should mean that more customers are buying, more programs are expanding, or more products are reaching commercial scale.
Funding still tells us something. So do new facilities, scientific breakthroughs and valuations. We just give them less weight unless they translate into commercial activity.
That distinction removes some obvious but misleading candidates. Generate Biomedicines has become a public company, so it no longer fits a normal startup comparison. Twist Bioscience is public too, even though its recent numbers are among the cleanest growth data anywhere in synthetic biology: fiscal 2025 revenue rose 20% to $376.6 million, followed by more than 20% year-over-year quarterly growth and fourteen consecutive quarters of sequential revenue growth.
Ginkgo Bioworks is also public, and its recent trajectory points the other way. Revenue fell 25% in 2025, although part of the decline came from unusual deferred-revenue items.
So our comparison focuses on private companies and asks a harder question: where is commercial activity actually accelerating right now?
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Is Profluent the fastest-growing synthetic biology startup right now?
Yes. Profluent currently has the strongest overall growth momentum we found among private synthetic biology startups.
The speed is unusual. Profluent was founded in 2022 around generative models that design proteins, with gene editing becoming one of its first major commercial targets. It then raised $35 million of additional funding in 2024 and a $106 million Series B in 2025, bringing total funding to roughly $150 million.
Forge data puts the post-money value attached to the 2024 financing at about $155 million and the 2025 Series B at roughly $503 million. That is around a 3.2-fold increase in less than two years.
More important, Profluent kept adding outside validation while that financing accelerated. The company announced work with Integrated DNA Technologies, the Rett Syndrome Research Trust, Ensoma and Corteva before signing its much larger genetic-medicine collaboration with Eli Lilly. In July 2026, Profluent also highlighted an ARPA-H-backed program involving GEMMABio that uses Profluent-designed editing technology for rare liver diseases.
Funding, counterparties, therapeutic applications and the scope of Profluent-designed editors are all moving in the same direction. That is enough to put Profluent first for now.
| Profluent milestone | Scale |
|---|---|
| Additional financing in 2024 | $35M |
| Series B in 2025 | $106M |
| Total funding after Series B | ~$150M |
| Forge post-money value, 2024 financing | ~$155M |
| Forge post-money value, 2025 financing | ~$503M |
| Lilly potential deal value | Up to $2.25B |
If you want more recent data on this point, please see our latest synthetic biology market report.
Does Profluent’s $2.25 billion Lilly deal mean Profluent already has a huge business?
No. Profluent’s Lilly agreement makes the company much more credible commercially, but $2.25 billion is a potential milestone pool rather than $2.25 billion of current sales.
The distinction is essential. Pharmaceutical partnerships usually combine upfront payments, research funding, development milestones, regulatory milestones, commercial milestones and sometimes royalties. Many of those payments only arrive if molecules keep progressing for years.
The Lilly deal covers AI-designed recombinases for genetic medicines across multiple diseases. Bloomberg described the agreement as worth up to $2.25 billion, which tells us how much economic value could eventually be attached to successful programs. It tells us very little about Profluent’s revenue today.
The more interesting part is the sequence around Lilly. Profluent had already signed Ensoma for AI-designed base editors, Corteva around agricultural applications and IDT around protein-design technology. Lilly then pushed the company into a much larger pharmaceutical relationship.
That pattern makes Profluent look increasingly like a platform that large organizations are willing to build programs around. We would be much more cautious if the Lilly announcement stood alone.
This chart, featured in our synthetic biology market deck, illustrates yearly VC funding for synthetic biology startups
Could Cradle actually be growing faster than Profluent?
Yes. Cradle may already be growing faster than Profluent in recurring customer usage, and this is the closest challenge to Profluent’s lead.
Cradle sells AI protein-engineering software directly to scientific teams. That gives us better operating clues than we get from most private biotech companies.
When Cradle announced its $73 million Series B in late 2024, it said more than 21 customers were using the platform across 31 proteins. Customers included Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols.
By the end of 2025, Cradle said more than 50 projects were running on the platform and six of the world’s top 25 pharmaceutical companies were customers. The company had doubled headcount, expanded in the United States and, more importantly, converted several proof-of-concept projects into multiyear commitments. Existing customers were also putting more projects onto Cradle.
The expansion continued in 2026. Bayer signed a three-year collaboration covering therapeutic antibody work. Lundbeck then brought Cradle into two antibody programs for central nervous system diseases. The company has kept shipping new protein-engineering features as well, including Guided Rounds and additional antibody-design tools.
We cannot turn “31 proteins” and “50+ projects” into a precise growth percentage because the measurements are not identical. Still, the direction is hard to miss: more programs, bigger pharma customers and deeper deployments.
If Cradle eventually discloses strong recurring revenue growth, it could take the overall number-one position.
If you want more recent data on this point, please see our latest synthetic biology market report.
Are Cradle customers actually getting useful results from AI protein engineering?
Yes. Cradle now has enough wet-lab results to show that customers are getting more than an interesting software demo.
The strongest evidence comes from repeated protein-engineering programs rather than one benchmark. Cradle reports customers achieving two- to twelve-fold faster development cycles across more than 50 programs.
In one therapeutic peptide project for a top-20 pharmaceutical company, Cradle produced libraries with at least a 50% success rate against multiple constraints and completed in one round what the customer estimated would normally require five. Another program improved vaccine-protein thermostability by 2.5°C in a single round. A separate enzyme project produced a candidate with a 20°C improvement in melting temperature while also increasing expression and activity.
The published results come from Cradle itself, so they are not an unbiased sample of every customer project. What makes them more convincing is that large customers are extending deployments after testing the platform.
Bayer committed for three years. Earlier proofs of concept became multiyear contracts. Existing customers added programs.
For enterprise scientific software, repeat usage is the harder test, and Cradle is passing it so far.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Is Arzeda the clearest synthetic biology commercial breakout right now?
Arzeda has one of the strongest commercial growth stories in synthetic biology today because an AI-designed product has already captured measurable share of a real ingredient market.
Arzeda launched ViaLeaf Reb M, its stevia sweetener, in 2024. By 2025, the company said ViaLeaf sales had exceeded 5% of the global Reb M market. Production expanded to a second European site during the same year.
The story accelerated again in 2026. Arzeda first partnered with MANE, one of the world’s largest flavor and fragrance companies, to commercialize ViaLeaf. The partnership then deepened substantially: in July, MANE acquired an exclusive worldwide licence to produce and commercialize the ingredient, taking responsibility across the value chain from production through sales.
The production setup is already meaningful. A SynBioBeta report published through Arzeda described ViaLeaf capacity above 500 metric tonnes per year, making it one of the larger operating examples of cell-free biomanufacturing.
Arzeda has also launched a second product in another industrial vertical and is working with companies including Unilever, Takeda, W.L. Gore and KENT Specialty Milling.
That is a much more concrete commercial story than its funding profile alone would suggest. Arzeda has moved from designing proteins to putting an AI-enabled product into mainstream industrial distribution.
If you want more recent data on this point, please see our latest synthetic biology market report.
Could Arzeda be growing faster than Profluent if we only count real products?
Yes. Arzeda has a stronger case than Profluent if we judge growth mainly by products that customers can already buy at commercial scale.
Going from a 2024 launch to more than 5% of an established global ingredient category during 2025 is unusually concrete for synthetic biology. The subsequent MANE licence makes the path to wider distribution much stronger because Arzeda no longer has to build the entire manufacturing and global sales machine itself.
Arzeda’s model may also scale differently from the old synthetic biology playbook. Once a protein and process work, a large industrial partner can take over manufacturing and commercialization while Arzeda returns to designing the next product.
The limitation is financial visibility. We do not know Arzeda’s current revenue, how much of ViaLeaf economics stays with Arzeda under the MANE structure, or how large its second product has become.
So we can confidently call Arzeda the strongest product-commercialization story in this group. We cannot confidently say its company-wide business is expanding faster than Profluent’s or Cradle’s.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Is Antheia becoming a real pharmaceutical manufacturing company?
Yes. Antheia has already crossed from synthetic biology R&D into commercial pharmaceutical manufacturing, which relatively few startups in the field manage to do.
Antheia engineers yeast to produce complex pharmaceutical molecules that have traditionally depended on plant-based supply chains. Its first major commercial milestone came when the company delivered a full-scale order of thebaine, a starting material used to manufacture several medicines.
The company is now trying to repeat that model across a much larger pipeline. Antheia says it has more than 70 biosynthetic pharmaceutical ingredients under development across seven therapeutic areas and has partnered with Phlow on domestic production of several critical starting materials.
Capital is following that transition. Antheia completed an $80 million Series C after adding a $24 million second close in early 2026. Including government-backed project funding and other available capital, the company said it had secured more than $175 million over the preceding year.
That money is being directed toward commercial manufacturing capacity, additional late-stage ingredients and U.S. production.
The next proof point is straightforward: Antheia needs several molecules generating repeat commercial orders. One successful product proves the manufacturing approach can work. A growing portfolio would prove that Antheia can build a large business around it.
Is Solugen still ahead of newer synthetic biology startups?
Solugen is still one of the biggest industrial synthetic biology startups, although the freshest public evidence does not show that it is growing faster than Profluent, Cradle or Arzeda.
Solugen has already reached a physical scale that most younger companies have not. Its Bioforge process combines engineered enzymes with conventional catalysts to manufacture specialty chemicals, and its Houston facility has been operating for years.
Historical growth was exceptional. Solugen reportedly moved from roughly $12 million of revenue in 2019 to a run rate above $100 million in 2022 while serving more than 30 customers.
More recent evidence shows continued industrial activity, especially in defense. Solugen says one energetic-precursor program scaled fiftyfold in less than six months and delivered 7.5 million pounds in 2024. Its current defense materials describe capacity doubling within six months, 98.7% on-time delivery and a domestic manufacturing push across specialty chemicals and energetic precursors.
The company also has relationships with ADM, Sasol and Kurita.
What we still lack is a current revenue series comparable with the older figures. Solugen could be much larger today, but public information does not let us calculate how quickly the whole company has grown over the past two or three years.
That leaves Solugen as the industrial heavyweight rather than our current growth winner.
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Are AI protein-design startups pulling ahead of traditional synthetic biology?
AI protein-design companies are producing some of the fastest commercial expansion in synthetic biology because each new customer or molecule can be added without first building another large fermentation plant.
Profluent, Cradle and Arzeda show three versions of that advantage.
Profluent uses generative models to create new biological editing systems and monetizes them through partnerships. Cradle lets pharmaceutical and industrial scientists run protein optimization directly through software. Arzeda designs proteins and then turns selected designs into commercial ingredients.
Other companies are pushing in the same direction. Basecamp Research has built a biological dataset spanning more than 10 billion genes from over one million species and is working on a much larger Trillion Gene Atlas with partners including Nvidia and Anthropic. Adaptyv has raised $40 million to expand automated laboratories built to test AI-generated protein designs.
The bottleneck is shifting. Designing a plausible biological sequence is becoming easier, while generating high-quality experimental data and proving that the molecule works in the real world remain difficult.
That is one reason Cradle keeps investing in experiment-driven models and why Arzeda’s commercial product is so useful as evidence. Better algorithms help, but biology still has to survive the lab, manufacturing and customer use.
What did Ginkgo Bioworks teach us about synthetic biology growth?
Ginkgo Bioworks showed that a huge synthetic biology platform can accumulate programs and partners without producing the sustained commercial growth investors expected.
Ginkgo was once the clearest expression of the “biology as a programmable platform” idea. Its foundries were designed to engineer organisms for customers across many industries, and the company reached a multibillion-dollar public valuation.
The financial results eventually became much harder to reconcile with that story. Ginkgo reported $170 million of revenue in 2025, down 25% from $227 million the previous year. Adjusting for unusually large deferred-revenue releases makes the underlying Cell Engineering decline much smaller, but the business still was not growing.
Ginkgo has since cut costs and shifted more attention toward autonomous laboratories, AI models and tools that other scientists can use.
The lesson for today’s private companies is useful. More programs only become compelling when customers keep expanding them, products reach markets or recurring economics start appearing.
Cradle looks better today because several pilot projects became multiyear deployments. Arzeda has actual ingredient market share. Antheia has shipped commercial pharmaceutical material. Profluent has attracted increasingly valuable counterparties, although it still has the most to prove on recurring revenue.
That is a much tougher standard than counting partnership announcements.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
Which synthetic biology startups have the strongest growth evidence today?
Profluent, Cradle, Arzeda and Antheia currently have the strongest fresh growth evidence among the private synthetic biology companies we examined, with Solugen remaining an important industrial-scale contender.
The ranking becomes clearer once we separate what has actually been demonstrated.
Profluent wins on speed of strategic expansion. Cradle has the strongest evidence of increasing enterprise usage. Arzeda has the cleanest proof of a newly commercialized synthetic biology product taking real market share. Antheia has moved into commercial pharmaceutical supply. Solugen already operates on a larger industrial base but lacks a recent public growth rate.
The confidence is not equal across those conclusions. We are highly confident that Arzeda has reached commercial product scale and that Cradle is expanding usage because both companies disclose operating metrics. We have high confidence that Profluent’s strategic position has changed dramatically, while our confidence about its actual revenue growth is much lower.
| Startup | Freshest useful growth evidence | Our read |
|---|---|---|
| Profluent | Lilly, Ensoma, Corteva and newer therapeutic programs after rapid financing growth | Fastest overall acceleration |
| Cradle | 50+ projects, six top-25 pharma customers, Bayer and Lundbeck deployments | Strongest enterprise adoption |
| Arzeda | >5% Reb M share, >500-tonne capacity, exclusive MANE global licence | Strongest product commercialization |
| Antheia | Commercial thebaine, $80M Series C, manufacturing expansion | Strongest emerging pharma manufacturing |
| Solugen | Multi-million-pound defense deliveries and operating Bioforge capacity | Largest industrial contender, recent growth unclear |
What could knock Profluent off the top spot?
Cradle or Arzeda could overtake Profluent quickly if either company starts disclosing strong revenue growth, because Profluent’s current lead still rests heavily on partnerships whose biggest economics are in the future.
Gene-editing programs face a long chain of technical and clinical risks. A Profluent-designed system has to work biologically, perform well enough to justify continued development, survive preclinical testing and eventually reach patients before the largest pharmaceutical milestones become relevant.
Competition is also getting much stronger. Isomorphic Labs raised $2.1 billion in 2026 to scale AI drug design. Generate Biomedicines reached the public market. Basecamp Research, Cradle and many academic groups are pushing biological foundation models and protein design forward at the same time.
Cradle has a simpler route to near-term commercial proof because scientists can buy and expand software before a medicine reaches the clinic. Arzeda has an even more tangible benchmark: customers can already buy the product.
So Profluent needs another kind of evidence next. We want to see partners expanding programs, editors advancing further through development and eventually enough disclosed economics to separate genuine business growth from exceptionally strong dealmaking.
For now, the dealmaking is strong enough to keep Profluent first.
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
Which synthetic biology startup is growing the fastest?
Profluent is the fastest-growing private synthetic biology startup we can identify today, with Cradle close behind and Arzeda now making a surprisingly strong case from actual product commercialization.
Profluent gets our number-one spot because several things have accelerated at once since 2024: funding, implied private valuation, the number of serious counterparties and the commercial importance of the programs those partners are pursuing. As seen above, the Lilly agreement is only one part of that trajectory rather than the reason for the entire conclusion.
Cradle comes second, and we would not be surprised if better financial disclosure eventually pushed it into first place. More than 50 projects, six top-25 pharmaceutical customers, multiyear expansions and newer deployments with Bayer and Lundbeck look like a genuine enterprise adoption curve.
Arzeda deserves third place overall but first place for commercial product proof. Its ViaLeaf launch, rapid penetration of the Reb M market, industrial-scale capacity and expanded MANE relationship form the cleanest sequence from AI-designed biology to a product being produced and sold globally.
Antheia follows because it has already made the difficult jump into commercial pharmaceutical manufacturing. Solugen remains bigger and more industrially mature than most of these companies, but we cannot verify a fresh company-wide growth rate strongly enough to put it at the top.
Our answer therefore depends slightly on what the reader cares about. For overall momentum, Profluent is first. For enterprise customer expansion, Cradle looks strongest. For hard evidence that a new synthetic biology product is taking market share, Arzeda has the best case.
If we have to give one name, Profluent is still the answer today.
OUR METHODOLOGY
There is no single metric that cleanly answers which synthetic biology startup is growing the fastest. Rather than rely on intuition, reputation, funding headlines or a general sense of momentum, we broke the question into the dimensions that actually show whether a company is expanding.
For each dimension, we looked for the freshest meaningful evidence available and assessed it independently before forming an overall view. We prioritized commercial adoption, customer expansion, product deployment, production scale, program growth and strategic validation. Financing and private-market valuations were supporting evidence, not substitutes for operating progress.
We also separated scale from acceleration. A company can already be large without currently growing the fastest, while a younger company can be expanding rapidly from a much smaller base. Recent evidence therefore carried more weight, with older figures used mainly to establish context. Where disclosures measured different things, we treated them directionally rather than forcing them into a fake precision.
The ranking was built from the combined weight of several indicators rather than from one announcement or a mechanical score. We looked for multiple recent developments pointing in the same direction, avoided counting the same underlying event more than once, and checked whether apparent momentum was being reinforced by customers, partners, products or follow-on activity. Public companies such as Twist Bioscience, Ginkgo Bioworks and Generate Biomedicines were used as benchmarks, but the final ranking itself was kept to private startups.
For sourcing, we prioritized first-hand company and counterparty disclosures, regulatory filings, government records and other authoritative primary material. Specialist private-market data was used where information such as financing valuations is not normally disclosed publicly.
Key sources include SynBioBeta’s 2025 investment report, Generate Biomedicines’ SEC IPO prospectus, Twist Bioscience’s fiscal 2025 filing, Ginkgo Bioworks’ 2025 earnings release, Profluent’s Series B announcement, Forge’s Profluent private-market data, Profluent’s Eli Lilly partnership announcement, IDT’s Profluent collaboration announcement, and ARPA-H on the GEMMABio program.
For Cradle, we used its Series B disclosure, its 2025 operating update, the Bayer collaboration, and the Lundbeck partnership. For Arzeda, we used its company milestones, MANE’s initial ViaLeaf partnership announcement, and Arzeda’s announcement of the expanded exclusive global licence.
For Antheia, we used its initial Series C announcement, the Series C second close and commercial thebaine update, and Phlow’s announcement of the Antheia partnership. For Solugen, we used its aerospace and defense operating data.
Additional context came from Basecamp Research’s biological dataset disclosures, Isomorphic Labs’ funding announcement, and Adaptyv Bio’s company updates. The final answer is a bottom-up judgment built from those operating, commercial and financing datapoints together rather than from any single headline.
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
